吉非替尼与厄洛替尼治疗非小细胞肺癌效果的间接比较

目的系统评价吉非替尼与厄洛替尼治疗非小细胞肺癌的临床效果.方法检索国内外公开发表的关于吉非替尼或厄洛替尼治疗非小细胞肺癌的中英文文献,采用Bucher法对纳入的研究进行间接比较.结果共纳入4项吉非替尼vs标准治疗和3项厄洛替尼vs标准治疗的文献进行间接比较.吉非替尼与厄洛替尼治疗非小细胞肺癌的反应率和疾病控制率的 RR 值分别为0.56（P=0.0536）、0.87（P=0.6745）,中位生存期和中位无发展生存期的 MD 值分别为-0.31（P=0.7718）、-3.93（P=0.1443）.结论尽管间接比较存在一定的局限性,但结果表明吉非替尼与厄洛替尼治疗非小细胞肺癌的效果无显著性差异.

Indirect Comparisons for Efficacy of Gefitinib and Erlotinib in Patients with Non-small Cell Lung Cancer

Objective Systematically evaluate the efficacy of Gefitinib and Erlotinib in patients with non-small cell lung cancer（NSCLC）. Methods Inputs for the indirect comparisons were chosen from the literature published both in the domestic and overseas about Gefitinib and Erlotinib in patients with NSCLC.Bucher method was used to conduct the indirect comparisons. Results Four literatures about Gefitinib vs standard medicine and three literatures about Erlotinib vs standard medicine were chosen for indirect comparisons.The RR of response rate and disease control rate between Gefitinib and Erlotinib in patients with NSCLC were 0.56 ~ P=-0.0536）, 0.87（P=-0.6745）, respectively. The MD of median survival and median progression-free survival were -0.31 （P=-0.7718）, -3.93 （P=-0.1443）, respectively. Conclusion Notwithstanding the limitations of an indirect comparison study, it showed no profound significant differences in efficacy between Gefitinib and Erlotinib in patients with NSCLC.